Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...

Tandem Diabetes is driving transformative innovation to help reduce the burden of diabetes and create new possibilities for ...

The t:slim X2 pump is currently cleared for use with Humalog and Novolog/NovoRapid U-100 insulins globally, and Admelog/Insulin lispro Sanofi and Trurapi/Insulin aspart Sanofi U-100 insulins in Canada ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the launch of the third season of Dexcom U, the company's ...

Embecta said its patch pump was designed with feedback from people with Type 2 diabetes. The company presented data in June finding that 200-unit reservoirs have enough capacity for only 38% of adults ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

DexCom faces significant headwinds, including slower customer growth and increased competition. Learn more on DXCM here.

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...